Identification of Aggravation-Predicting Gene Polymorphisms in Coronavirus Disease 2019 Patients Using a Candidate Gene Approach Associated With Multiple Phase Pathogenesis: A Study in a Japanese City of 1 Million People
IMPORTANCE:. The pathology caused by the coronavirus disease 2019 is mediated by host-mediated lung inflammation, driving severity, and mortality. Polymorphisms in genes encoding host inflammation and immune-related molecules may be associated with the development of serious pathologies, and identif...
Guardado en:
Autores principales: | Naoki Tanimine, MD, PhD, Daisuke Takei, MD, Naohumi Tsukiyama, MD, Hisaaki Yoshinaka, MD, Yuki Takemoto, MD, Yuka Tanaka, PhD, Tsuyoshi Kobayashi, MD, PhD, Kazuaki Tanabe, MD, PhD, Nobuhisa Ishikawa, MD, PhD, Yoshihiro Kitahara, MD, PhD, Mafumi Okimoto, MD, Nobuaki Shime, MD, PhD, Hiroki Ohge, MD, PhD, Aya Sugiyama, MD, PhD, Tomoyuki Akita, PhD, Junko Tanaka, PhD, Hideki Ohdan, MD, PhD |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wolters Kluwer
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/12e1fdf3a6344ad6aff40336c40788b1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Fewer Intubations but Higher Mortality Among Intubated Coronavirus Disease 2019 Patients During the Second Than the First Wave
por: Christina Routsi, MD, PhD, et al.
Publicado: (2021) -
Detectable A Disintegrin and Metalloproteinase With Thrombospondin Motifs-1 in Serum Is Associated With Adverse Outcome in Pediatric Sepsis
por: Navin P. Boeddha, MD, PhD, et al.
Publicado: (2021) -
Effect of Inhaled Xenon on Cardiac Function in Comatose Survivors of Out-of-Hospital Cardiac Arrest—A Substudy of the Xenon in Combination With Hypothermia After Cardiac Arrest Trial
por: Antti Saraste, MD, PhD, et al.
Publicado: (2021) -
Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin?
por: Nikolai Ravn Aarskog, MD, et al.
Publicado: (2021) -
MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Katsuhiro Yoshimura, MD, PhD, et al.
Publicado: (2021)